Lisen Imprinting Diagnostics Email Format

Biotechnology ResearchDelaware, United States2-10 Employees

Lisen Imprinting Diagnostics is a biotechnology research company based in Wilmington, Delaware, focused on reducing indeterminate cancer diagnoses. The company combines epigenetic imprinting biomarkers with artificial intelligence to offer a molecular test and accompanying machine-learning platform that aims to detect carcinogenesis at its onset in routine tumor biopsy samples and to predict cancer risk with up to 95% accuracy. Its approach is designed to be scalable across as many as 13 cancer types and applicable in both screening and diagnostic workflows, assisting clinicians and pathologists in making timely, well-founded decisions.
The business targets clinicians and pathology professionals who work with tumor biopsies, situating itself in the biotechnology research landscape focused on cancer diagnostics. In November 2025, Merck entered into a partnership with Lisen Imprinting Diagnostics to collaborate through Merck's China Innovation Hub, signaling potential expansion of collaboration in Asia.

Sign up for free to view info

Company overview Employee directory